Side-by-Side Comparison
CJC-1295 vs Ipamorelin: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how CJC-1295 and Ipamorelin differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
CJC-1295
L3Also: CJC-1295 DAC, CJC-1295 without DAC, Modified GRF 1-29
A growth hormone-releasing hormone (GHRH) analog studied for its ability to increase growth hormone and IGF-1 levels.
Also: NNC 26-0161
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.
Side-by-side comparison
| Attribute | CJC-1295 | Ipamorelin |
|---|---|---|
| Primary mechanism | GHRH Receptor Agonism | Ghrelin Receptor Agonism |
| FDA status | Banned from Compounding (Category 2) | Banned from Compounding (Category 2) |
| Evidence level | Emerging Clinical Evidence | Emerging Clinical Evidence |
| Human trials | Yes (3+ indexed) | Yes (2+ indexed) |
| Studies indexed | 24 total (5 human, 12 animal) | 33 total (4 human, 18 animal) |
| Primary uses researched | Growth hormone release, Body composition, Recovery | Growth hormone release, Body composition, Sleep quality, Recovery |
| Administration routes | subcutaneous | subcutaneous |
| Molecular weight | 3367.97 Da | 711.85 Da |
| Amino acids | 30 | 5 |
| Category | growth hormone | growth hormone |
| WADA status | Prohibited | Prohibited |
Key differences
Mechanism. CJC-1295 acts primarily through ghrh receptor agonism, while Ipamorelin acts primarily through ghrelin receptor agonism. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. Both compounds share the same FDA status (Banned from Compounding (Category 2)), which means the practical pathway to access is similar for each.
Evidence base. Both compounds currently sit at L3 (Emerging Clinical Evidence) on PeptideMark's methodology.
Research focus. Published research on CJC-1295 has concentrated on growth hormone release, body composition, recovery. Research on Ipamorelin has concentrated on growth hormone release, body composition, sleep quality. There is meaningful overlap between the two research programs, which is why these compounds are frequently compared.
Safety snapshot
| Attribute | CJC-1295 | Ipamorelin |
|---|---|---|
| Documented effects | 8 total | 6 total |
| Serious events | 0 | 0 |
| Common events | 2 | 1 |
| Black box warning | No | No |
| Contraindications | 4 listed | 3 listed |
| Drug interactions | 2 flagged | 2 flagged |
| Most common event | Injection site reactions | Injection site reactions |
Strengths & limitations
CJC-1295
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Restricted from compounding pharmacies (FDA Category 2)
- Prohibited in competitive sport under WADA
Ipamorelin
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Restricted from compounding pharmacies (FDA Category 2)
- Few human trials — most data is preclinical
- Prohibited in competitive sport under WADA
Representative studies
CJC-1295
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, Neale A, Lawrence B, et al. · Journal of Clinical Endocrinology & Metabolism (2006)
CJC-1295 DAC produced dose-dependent, sustained increases in GH and IGF-1 with cumulative effects from repeated dosing — the foundational human pharmacokinetic data.
PubMed 16352683Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Ionescu M, Bhatt DL. · Journal of Clinical Endocrinology & Metabolism (2006)
CJC-1295 preserves pulsatile GH secretion during continuous stimulation — the enhanced trough GH levels (not pulse amplitude) drive the IGF-1 increase.
PubMed 17018654Ipamorelin
Ipamorelin, a new growth-hormone-releasing peptide, induces growth hormone release in a specific and selective manner
Raun K, Hansen BS, Johansen NL, et al. · Journal of Endocrinology (1998)
Ipamorelin demonstrated true GH selectivity: no cortisol/ACTH/prolactin elevation even at supramaximal doses, establishing it as the cleanest GHRP.
PubMed 9725926Ipamorelin, the first selective growth hormone secretagogue
Johansen PB, Nowak J, Skjærbæk C, et al. · European Journal of Endocrinology (1999)
Confirmed ipamorelin as the first truly selective GH secretagogue, with a selectivity window exceeding 200-fold between GH release and cortisol stimulation.
PubMed 10580762Frequently asked
What is the main difference between CJC-1295 and Ipamorelin?
CJC-1295 is a growth hormone-releasing hormone (ghrh) analog studied for its ability to increase growth hormone and igf-1 levels. Its primary mechanism is ghrh receptor agonism. Ipamorelin is a selective growth hormone secretagogue that stimulates gh release without significantly affecting cortisol or prolactin. Its primary mechanism is ghrelin receptor agonism. The two differ in regulatory status (Banned from Compounding (Category 2) vs Banned from Compounding (Category 2)), strength of evidence (L3 vs L3), and the primary conditions for which each is researched.
Is CJC-1295 or Ipamorelin FDA approved?
CJC-1295: Placed on FDA Category 2 list. Not approved for human use. Previously available from compounding pharmacies as a growth hormone secretagogue. Ipamorelin: Placed on FDA Category 2 list in late 2023. Not approved for human use.
How does the evidence base compare?
CJC-1295 has 24 indexed studies (5 human, 12 animal) and is rated Emerging Clinical Evidence. Ipamorelin has 33 indexed studies (4 human, 18 animal) and is rated Emerging Clinical Evidence. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can CJC-1295 and Ipamorelin be compared directly?
Yes — both compounds share the growth hormone category, meaning head-to-head comparisons are meaningful for the same therapeutic targets. Direct head-to-head trials between peptides are rare, however, so most comparisons rely on separate trial datasets rather than direct RCT data.
Are CJC-1295 and Ipamorelin commonly stacked together?
Yes — published literature and clinical practice sometimes combine CJC-1295 and Ipamorelin, typically for complementary mechanisms. Stacking should only be undertaken under qualified medical supervision, and evidence for combined safety is usually weaker than evidence for either compound alone.
Which has a better-documented safety profile, CJC-1295 or Ipamorelin?
CJC-1295 has 8 documented side effects (0 serious). Ipamorelin has 6 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are CJC-1295 and Ipamorelin administered?
Both are administered via subcutaneous. Practical dosing differences come down to frequency, concentration, and titration schedule rather than route of administration.
Which is better, CJC-1295 or Ipamorelin?
"Better" depends on the therapeutic goal, regulatory context, and individual response. CJC-1295 is most researched for growth hormone release and body composition; Ipamorelin is most researched for growth hormone release and body composition. FDA status also matters: Banned from Compounding (Category 2) for CJC-1295 vs Banned from Compounding (Category 2) for Ipamorelin. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
CJC-1295 →
Full profile
Ipamorelin →